ClinicalTrials.gg
CompletedNCT00298766Updated Jun 25, 2012Results posted

Open-Label Phase 1/2 Study of VELCADE for Injection in Patients With Light-chain (AL)-Amyloidosis

A Phase 1/2 interventional study of VELCADE in Amyloidosis, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-06-25.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
70
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 141 studies in Amyloidosis with a site in United States — 39 open to participants now, 47 under way, 10 of them phase 3. Amyloidosis · United States.

Enrollment
43rd of 99
70 · median 45
Started
2005
with 2 others
Phase 1/2
12 of 141
4 open now
Registered
7th of 141
by date

Among the 141 studies in Amyloidosis with a site in United States, this one is the 43rd largest by enrollment of the 99 interventional ones that give a count, is one of 3 that started in 2005, is one of 12 in phase 1/2, and was the 7th registered.

Amyloidosis

290 studies on the registry are indexed under Amyloidosis; 92 are open to participants now.

Browse Amyloidosis studies →

Open to participants now

39 of the 141 studies in Amyloidosis with a site in United States are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 70 Amyloidosis studies recruiting now, 43 (61%) set no upper age limit and 3 (4%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 141 studies in Amyloidosis with a site in United States, or all of them as a file.
02

Study summary

This is a phase 1/2 open-label, dose-escalation study investigating single-agent therapy with VELCADE in patients with previously treated systemic AL-amyloidosis who require further treatment.

03

Conditions studied

  • Amyloidosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or Female 18 y/o and older
  2. Female patients must be practicing an effective method of
  3. -proven AL-amyloidosis
  4. Must have been previously treated (failed at least 1 previous treatment) and in the opinion of the physician, patient requires further treatment

Exclusion criteria

Exclusion Criteria:

  1. to boron or mannitol
  2. Prior treatment with VELCADE
  3. Patient requires other concomitant chemotherapy, radiotherapy or ancillary therapy considered
  4. Uncontrolled infection
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    1

    VELCADE

    Drug: VELCADE

Interventions

  • Once weekly at: 0.7, 1.0, 1.3 or 1.6 mg/m2 Or Twice-weekly at: 0.7, 1.0, or 1.3 mg/m2

    Also known as: Bortezomib

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose

    Maximum Tolerated Dose (MTD) was defined as the highest dose level that has 0/1 out of 6 patients experiences Dose Limited Toxicity (DLT). MTD is defined separately for QW and BIQ dose cohorts. DLT was defined as adverse events occurring during Cycle 1 and: (1) related to VELCADE, (2) Grade 4 thrombocytopenia or neutropenia, (3) Grade 3 or higher nonhematologic toxicity.

    Time frame: 5 weeks in once weekly (QW) dose cohorts and 3 weeks in twice weekly (BIW) dose cohorts

  2. Subjects With Treatment Emergent Adverse Events

    Treatment emergent adverse events observed during outcome measure time frame

    Time frame: from first study-related procedure to 30 days after last dose of study medication

  3. Subjects With Serious Treatment Emergent Adverse Events

    Serious treatment emergent adverse events observed during outcome measure time frame

    Time frame: from first study-related procedure to 30 days after last dose of study medication

  4. Subjects Grade 3/4/5 Treatment Emergent Adverse Events

    Grade 3/4/5 treatment emergent adverse events observed during outcome measure time frame. Grade is determined according to Common Terminology Criteria for Adverse Event (CTCAE) Version 3.0.

    Time frame: from first study-related procedure to 30 days after last dose of study medication

  5. Subjects With Treatment Emergent Adverse Events Leading to Treatment Termination

    Treatment emergent adverse events observed during outcome measure time frame leading to treatment termination

    Time frame: from first study-related procedure to 30 days after last dose of study medication

Secondary outcomes

  1. Best Confirmed Hematologic Responders

    Hematologic response was determined by the investigator per the response criteria for immunoglobulin light chain amyloidosis by Gertz (2005). It include Complete and Partial Responders (CR+PR). CR requires serum and urine negative for a monoclonal protein by immunofixation and free light chain ratio normal. PR requires: 1. reduction in quantitative serum M-protein by 50% if baseline value is at least 0.5 g/dL, 2. if light chain is detected in the urine (with a consistent peak and \>100 mg/ 24 hours), then 50% reduction is required, 3. if free light chain \>10 mg/dL, reduction by 50% is required.

    Time frame: from first dose of study medication to end of study visit

07

Results

Posted Aug 13, 2010

Participant flow

Participant flow — Overall Study
MilestoneSingle Agent VELCADE
Started70
Completed24
Not completed46
Withdrew: Adverse event18
Withdrew: Death2
Withdrew: Withdrawal by subject9
Withdrew: Treatment ongoing4
Withdrew: Progression of amyloid markers4
Withdrew: Deterioration in kps and organ function1
Withdrew: Subjects overall condition deterioration4
Withdrew: Other4

Outcome measures

PrimaryMaximum Tolerated Dose

Maximum Tolerated Dose (MTD) was defined as the highest dose level that has 0/1 out of 6 patients experiences Dose Limited Toxicity (DLT). MTD is defined separately for QW and BIQ dose cohorts. DLT was defined as adverse events occurring during Cycle 1 and: (1) related to VELCADE, (2) Grade 4 thrombocytopenia or neutropenia, (3) Grade 3 or higher nonhematologic toxicity.

Time frame:
5 weeks in once weekly (QW) dose cohorts and 3 weeks in twice weekly (BIW) dose cohorts
Reported as:
Number · participants with DLT
Maximum Tolerated Dose
participants with DLTSingle Agent VELCADE
Maximum Tolerated Dose2
PrimarySubjects With Treatment Emergent Adverse Events

Treatment emergent adverse events observed during outcome measure time frame

Time frame:
from first study-related procedure to 30 days after last dose of study medication
Reported as:
Number · participants
Subjects With Treatment Emergent Adverse Events
participantsSingle Agent VELCADE
Subjects With Treatment Emergent Adverse Events70
SecondaryBest Confirmed Hematologic Responders

Hematologic response was determined by the investigator per the response criteria for immunoglobulin light chain amyloidosis by Gertz (2005). It include Complete and Partial Responders (CR+PR). CR requires serum and urine negative for a monoclonal protein by immunofixation and free light chain ratio normal. PR requires: 1. reduction in quantitative serum M-protein by 50% if baseline value is at least 0.5 g/dL, 2. if light chain is detected in the urine (with a consistent peak and \>100 mg/ 24 hours), then 50% reduction is required, 3. if free light chain \>10 mg/dL, reduction by 50% is required.

Time frame:
from first dose of study medication to end of study visit
Reported as:
Number · participants responded
Best Confirmed Hematologic Responders
participants respondedSingle Agent VELCADE
Best Confirmed Hematologic Responders33
PrimarySubjects With Serious Treatment Emergent Adverse Events

Serious treatment emergent adverse events observed during outcome measure time frame

Time frame:
from first study-related procedure to 30 days after last dose of study medication
Reported as:
Number · participants
Subjects With Serious Treatment Emergent Adverse Events
participantsSingle Agent VELCADE
Subjects With Serious Treatment Emergent Adverse Events25
PrimarySubjects Grade 3/4/5 Treatment Emergent Adverse Events

Grade 3/4/5 treatment emergent adverse events observed during outcome measure time frame. Grade is determined according to Common Terminology Criteria for Adverse Event (CTCAE) Version 3.0.

Time frame:
from first study-related procedure to 30 days after last dose of study medication
Reported as:
Number · participants
Subjects Grade 3/4/5 Treatment Emergent Adverse Events
participantsSingle Agent VELCADE
Subjects Grade 3/4/5 Treatment Emergent Adverse Events43
PrimarySubjects With Treatment Emergent Adverse Events Leading to Treatment Termination

Treatment emergent adverse events observed during outcome measure time frame leading to treatment termination

Time frame:
from first study-related procedure to 30 days after last dose of study medication
Reported as:
Number · participants
Subjects With Treatment Emergent Adverse Events Leading to Treatment Termination
participantsSingle Agent VELCADE
Subjects With Treatment Emergent Adverse Events Leading to Treatment Termination23

Adverse events

Collected over from first study-related procedure to 30 days after last dose of study medication. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Single Agent VELCADE—25/70 (35.7%)70/70 (100%)
Most frequent serious events
Showing 10 of 42
Most frequent serious events
EventSingle Agent VELCADE
PneumoniaInfections and infestations3/70
DiarrhoeaGastrointestinal disorders2/70
VomitingGastrointestinal disorders2/70
Renal failure acuteRenal and urinary disorders2/70
HypotensionVascular disorders2/70
ThrombocytopeniaBlood and lymphatic system disorders1/70
Atrial fibrillationCardiac disorders1/70
Cardiac failure acuteCardiac disorders1/70
Cardiac failure cogestiveCardiac disorders1/70
Restrictive cardiomyopathyCardiac disorders1/70
Most frequent other events
Showing 10 of 58
Most frequent other events
EventSingle Agent VELCADE
DizzinessNervous system disorders21/70
Pain in extremityMusculoskeletal and connective tissue disorders19/70
CoughRespiratory, thoracic and mediastinal disorders19/70
ParaesthesiaNervous system disorders17/70
Oedema peripheralGeneral disorders16/70
HeadacheNervous system disorders16/70
OedemaGeneral disorders15/70
Back painMusculoskeletal and connective tissue disorders13/70
Abdominal distensionGastrointestinal disorders12/70
PyrexiaGeneral disorders12/70

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Single Agent VELCADE
<=18 years0
Between 18 and 65 years43
>=65 years27
Age Continuous
Age Continuous(years)Single Agent VELCADE
Mean61 ± 10.10
Sex: Female, Male
Sex: Female, Male(Participants)Single Agent VELCADE
Female31
Male39
Region of Enrollment
Region of Enrollment(participants)Single Agent VELCADE
United States35
Canada8
France3
Germany11
Italy9
Spain4
08

Study locations

4 sites
  • Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute
    Los Angeles, California 90049, United States
  • Winship Cancer Center - Emory Clinic School of Medicine
    Atlanta, Georgia 30322, United States
  • Boston Medical Center
    Boston, Massachusetts 02118, United States
  • MSKCC
    New York, New York 10017, United States
09

References and documents

Publications

  • Reece DE, Hegenbart U, Sanchorawala V, Merlini G, Palladini G, Blade J, Fermand JP, Hassoun H, Heffner L, Kukreti V, Vescio RA, Pei L, Enny C, Esseltine DL, van de Velde H, Cakana A, Comenzo RL. Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis. Blood. 2014 Oct 16;124(16):2498-506. doi: 10.1182/blood-2014-04-568329. Epub 2014 Sep 8. PubMed 25202139 ↗
  • Reece DE, Hegenbart U, Sanchorawala V, Merlini G, Palladini G, Blade J, Fermand JP, Hassoun H, Heffner L, Vescio RA, Liu K, Enny C, Esseltine DL, van de Velde H, Cakana A, Comenzo RL. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood. 2011 Jul 28;118(4):865-73. doi: 10.1182/blood-2011-02-334227. Epub 2011 May 11. PubMed 21562045 ↗
  • Reece DE, Sanchorawala V, Hegenbart U, Merlini G, Palladini G, Fermand JP, Vescio RA, Liu X, Elsayed YA, Cakana A, Comenzo RL; VELCADE CAN2007 Study Group. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood. 2009 Aug 20;114(8):1489-97. doi: 10.1182/blood-2009-02-203398. Epub 2009 Jun 4. PubMed 19498019 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2005, a primary completion of Jul 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2010, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2006
First posted
Mar 3, 2006
Start
Jun 2005
Primary completionActual
Jul 2009
CompletionActual
Sep 2009
Results first posted
Aug 13, 2010
Last update
Jun 25, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00298766
Responsible party
Sponsor
First posted
Mar 3, 2006
Start date
Jun 2005
Primary completion
Jul 2009
Completion
Sep 2009
Results posted
Aug 13, 2010
Last update
Jun 25, 2012

Study contacts

Medical Monitor
study director · Millennium Pharmaceuticals, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bortezomib

Start the discussion